Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival

Journal of the National Cancer Institute

Volumn 90, Issue 11, 1998, Pages 824-832

  Grandis, Jennifer Rubin ^a,c   Melhem, Mona F ^b   Gooding, William E ^a   Day, Roger ^a   Holst, Valerie A ^b   Wagener, Marilyn M ^b   Drenning, Stephanie D ^b   Tweardy, David J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c University of Pittsburgh School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; SQUAMOUS CELL CARCINOMA;

EID: 0032478998     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.11.824     Document Type: Article

References (57)

1. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 1996;77:834-42.
2. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:429-35.
3. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4477-80.
4. Donath D, Vuong T, Shenouda G, MacDonald B, Tabah R. The potential uses of high-dose-rate brachytherapy in patients with head and neck cancer. Eur Arch Otorhinolaryngol 1995;252:321-4.
5. Fukazawa H, Ohashi Y, Sekiyama S, Hoshi H, Abe M, Takahashi M, Sato T. Multidisciplinary treatment of head and neck cancer using BCG, OK-432, and GE-132 as biologic response modifiers. Head Neck 1994;16:30-8.
6. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85:95-111.
7. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996;7:133-41.
8. Grandis JR, Tweardy DJ. Elevated level of transforming growth factor-alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53: 3579-84.
9. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284-92.
10. Rubin Grandis J, Chakraborty A, Zeng Q, Melhem MF, Tweardy DJ. Downmodulation of TGF-protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 1998;68:1-8.
11. Rubin Grandis J, Chakraborty A, Melhem MF, Zeng Q, Tweardy DJ. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 1997;15:409-16.
12. Sobin LH, Hermanek P, Hutter RV. TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer 1988;61:2310-4.
13. Gusterson B, Cowley G, Smith JA, Ozanne B. Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep 1984;8:649-58.
14. Lin CR, Chen WS, Kruiger W, Stolarsky LS, Weber W, Evans RM, et al. Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science 1984;64:843-8.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35: 1-39.
17. Westfall P, Young S. Resampling-based multiple testing. New York: John Wiley & Sons, 1993:62-75.
18. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972;74:187-220.
19. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987;1:1398-402.
20. Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WL, Foekens JA. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 1994;29:73-83.
21. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994;29: 41-9.
22. Nicholson S, Halcrow P, Sainsbury JR, Angus B, Chambers P, Farndon JR, et al. Epidermal growth factor receptor (EGF) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer 1988;58:810-4.
23. Toi M, Osaki A, Yamada H, Toge T. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 1991; 27:977-80.
24. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana C, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995;1:19-31.
25. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990;65:1619-25.
26. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69: 1120-5.
27. Mellon K, Wright C, Kelly P, Horne CH, Neal DE. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995;153(3 Pt 2):919-25.
28. Ravery V, Colombel M, Popov Z, Bastuji S, Patard JJ, Bellot J, et al. Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. Br J Cancer 1995;71:196-200.
29. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987;55:513-6.
30. Lager DJ, Slagel DD, Palechek PL. The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod Pathol 1994;7:544-8.
31. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996;73:301-6.
32. Fuller GN, Bigner SH. Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat Res 1992;276:299-306.
33. Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahdi AM. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 1996;34:809-15.
34. Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL. Prognostic value of epidermal growth factors receptor expression in cervical carcinoma. J Clin Pathol 1993;46:149-53.
35. Kristensen GB, Holm R, Abeler VM, Trope CG. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996;78:433-40.
36. Khalifa MA, Abdoh AA, Mannel RS, Haraway SD, Walker JL, Min KW. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer 1994;73:370-6.
37. Niikura H, Sasano H, Matsunaga G, Watanabe K, Ito K, Sato S, et al. Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. Hum Pathol 1995;26:892-6.
38. Iihara K, Shiozaki H, Tahara H, Kobayashi K, Inoue M, Tamura S, et al. Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 1993;71:2902-9.
39. Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, et al. Expression of epidermal growth factor receptor in human gastric and colonie carcinomas. Cancer Res 1988;48:137-41.
40. Yonemura Y, Takamura H, Ninomiya I, Fushida S, Tsugawa K, Kaji M, et al. Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer. Oncology 1992;49: 157-61.
41. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-9.
42. Akslen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995;76:1643-54.
43. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994;25:1075-83.
44. Todd R, Donoff BR, Gertz R, Chang AL, Chow P, Matossian K, et al. TGF-alpha and EGF-receptor mRNAs in human oral cancers. Carcinogenesis 1989;10:1553-6.
45. Santini J, Formento JL, Francoual M, Milano G, Schneider M, Dassonville O, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13:132-9.
46. Miyaguchi M, Olofsson J, Hellquist HB. Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy. Clin Otolaryngol 1991;16:466-9.
47. Maurizi M, Scambia G, Benedetti Panici P, Ferrandina G, Almadori G, Paludetti G, et al. EGF receptor expression in primary laryngeal cancer: correlation with clinico-pathological features and prognostic significance. Int J Cancer 1992;52:862-6.
48. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11: 1873-8.
49. Issing WJ, Liebich C, Wustrow TP, Ullrich A. Coexpression of epidermal growth factor receptor and TGF-alpha and survival in upper aerodigestive tract cancer. Anticancer Res 1996;16:283-8.
50. Wen QH, Miwa T, Yoshizaki T, Nagayama I, Furukawa M, Nishijima H. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope 1996;106:884-8.
51. Lee CS, Redshaw A, Boag G. TGF-alpha immunoreactivity in laryngeal carcinoma: lack of prognostic value and correlation to EGF-receptor expression. Aust N Z J Surg 1996;66:464-8.
52. Esteban JM, Battifora H, Warsi Z, Bailey A, Bacus S. Quantification of estrogen receptors on paraffin-embedded tumors by image analysis. Mod Pathol 1991;4:53-7.
53. Esteban JM, Ahn C, Mehta P, Battifora H. Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol 1994;102:158-62.
54. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991;83:97-104.
55. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 1994;29:127-38.
56. Phillips PC, Levow C, Catterall M, Colvin OM, Pastan I, Brem H. Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res 1994;54: 1008-15.
57. Kameyama S, Kawamata H, Pastan I, Oyasu R. Cytotoxic effect of a fusion protein from transforming growth factor alpha and Pseudomonas exotoxin on rat and human bladder carcinoma cells in vitro. J Cancer Res Clin Oncol 1994;120:507-12.